Amgen Inc. (0R0T.IL)

273,00 0,00 (0,00%) Alla chiusura: 07:11PM BST

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 25.200

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Robert A. Bradway	Chairman, CEO & Pres	5,49M	N/D	1963
Mr. Peter H. Griffith	Exec. VP & CFO	2,57M	N/D	1959
Mr. Esteban Santos	Exec. VP of Operations	2,52M	N/D	1968
Dr. David M. Reese M.D.	Exec. VP of R&D	2,83M	N/D	1963
Mr. Murdo Gordon	Exec. VP of Global Commercial Operations	2,72M	N/D	1967
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Fin.	N/D	N/D	1974
Mr. Mike Zahigian	Sr. VP & Chief Information Officer	N/D	N/D	N/D
Mr. Arvind Sood	VP of Investor Relations	N/D	N/D	N/D
Mr. Jonathan P. Graham	Exec. VP, Gen. Counsel & Sec.	N/D	N/D	1961
Ms. Nancy A. Grygiel	Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Governance aziendale

L'ISS Governance QualityScore di Amgen Inc. al 1 ottobre 2023 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.